Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DoJ, Congress Want Ad Oversight: FDA Sounds Ready To Respond

Executive Summary

The Department of Justice's level of interest in drug industry promotional issues seems to be increasing, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told the Food & Drug Law Institute advertising and promotion conference Sept. 8

You may also be interested in...



Advertising Citations Reach Record High: Another Way To Regulate Pharma?

FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month

Advertising Citations Reach Record High: Another Way To Regulate Pharma?

FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month

FDA’s Advertising Enforcement Turns Its Focus To YouTube, ADHD Drugs

FDA's spate of five promotional citations to manufacturers of attention deficit/hyperactivity disorder drugs signals that the agency intends to remain vigilant in oversight of new media

Related Content

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel